Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q15928
UPID:
ZN141_HUMAN
Alternative names:
-
Alternative UPACC:
Q15928; Q6DK07
Background:
Zinc finger protein 141 plays a pivotal role in limb development and may function as a transcriptional repressor. Its involvement in the intricate processes of gene expression regulation underscores its importance in cellular mechanisms.
Therapeutic significance:
The association of Zinc finger protein 141 with Polydactyly, postaxial A6, highlights its clinical relevance. Understanding the role of Zinc finger protein 141 could open doors to potential therapeutic strategies for limb malformations.